Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Baxter
Moodys
Covington
Accenture
Chinese Patent Office
Express Scripts
Cantor Fitzgerald
Julphar
US Department of Justice

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,722,650

« Back to Dashboard

Which drugs does patent 8,722,650 protect, and when does it expire?

Patent 8,722,650 protects SOLODYN and is included in one NDA.

This patent has thirteen patent family members in ten countries.
Summary for Patent: 8,722,650
Title:Extended-release minocycline dosage forms
Abstract: An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Scottsdale, AZ), Newhard; Steven B. (Scottsdale, AZ), Watt; David (Scottsdale, AZ)
Assignee: Medicis Pharmaceutical Corporation (Bridgewater, NJ)
Application Number:12/861,424
Patent Claim Types:
see list of patent claims
Use; Formulation; Dosage form;

Drugs Protected by US Patent 8,722,650

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-008 Aug 27, 2010 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF ACNE ➤ Subscribe
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-007 Aug 27, 2010 AB RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF ACNE ➤ Subscribe
Medicis SOLODYN minocycline hydrochloride TABLET, EXTENDED RELEASE;ORAL 050808-006 Aug 27, 2010 AB RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF ACNE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,722,650

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,252,776 Minocycline oral dosage forms for the treatment of acne ➤ Subscribe
7,541,347 Minocycline oral dosage forms for the treatment of acne ➤ Subscribe
7,544,373 Minocycline oral dosage forms for the treatment of acne ➤ Subscribe
8,268,804 Minocycline oral dosage forms for the treatment of acne ➤ Subscribe
7,919,483 Method for the treatment of acne ➤ Subscribe
7,790,705 Minocycline oral dosage forms for the treatment of acne ➤ Subscribe
9,192,615 Method for the treatment of acne and certain dosage forms thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,722,650

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 101208097 ➤ Subscribe
European Patent Office 1898925 ➤ Subscribe
Israel 188331 ➤ Subscribe
Japan 2013213047 ➤ Subscribe
Japan 5744976 ➤ Subscribe
Japan 2008543936 ➤ Subscribe
Norway 20080444 ➤ Subscribe
New Zealand 564093 ➤ Subscribe
Canada 2613273 ➤ Subscribe
Australia 2006262428 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
Julphar
Covington
Mallinckrodt
US Army
Merck
Baxter
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot